Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 17 of the 45 sources its claims cite were checked for support.

Nitazene test strips: a laboratory evaluation

Open access
De Vrieze, Liam M., Stove, Christophe P., Vandeputte, Marthe M. · 2024 · Harm Reduction Journal

Abstract

BACKGROUND: 2-Benzylbenzimidazole 'nitazene' opioids pose a growing threat to public health. Nitazene analogues are increasingly found mixed with or (mis)sold as heroin and in falsified (non-)opioid medications, posing a great risk of intoxication in users (un)knowingly exposed to these potent opioids. Lateral flow immunoassay nitazene test strips (NTS; BTNX Rapid Response™) became commercially available in Q1 2024, with the aim to enable rapid detection of nitazene analogues in drug samples. As only limited independent data is available on the performance of these strips, this lab-based study aimed at evaluating their potential for drug checking applications. METHODS: Following dilution of drug standards in water, the NTS readouts were analyzed independently by two individuals and by ImageJ. The limit of detection for isotonitazene was determined using two manufacturing lots of NTS. Cross-reactivity with 32 other nitazene analogues was evaluated. Six sourced drug samples were tested to explore the ability of NTS to detect the presence of a nitazene analogue in authentic samples. RESULTS: The limits of detection for isotonitazene were 2000 or 3000 ng/mL, depending on the lot. Twenty-four of the 33 tested nitazene analogues cross-reacted with the NTS at concentrations ≤ 9000 ng/mL. Structural analysis indicated that either substitution or removal of the 5-nitro group, or lengthening the linker between the two aromatic rings, generally hampered detection. All six authentic drug samples consistently tested positive, with no observed false negatives. CONCLUSIONS: This study provides a better understanding of the potential of NTS for drug checking purposes. Our findings indicate that NTS can theoretically alert to the presence of most nitazene analogues that have emerged on recreational drug markets. However, 'desnitazenes' (lacking the 5-nitro group) may yield false negative results due to low cross-reactivity. Although factors like specificity, lot-to-lot variability, nitazene analogue content in drug samples, solubility, and different testing conditions should be considered, our study results indicate that, at least under the conditions evaluated here (using reference standards and sourced powders), NTS are capable of detecting the presence of a wide range of nitazene analogues. Hence, NTS may alert users of the presence of nitazene analogues in drug samples.

Overview

CoChat Summary

TL;DR

This laboratory evaluation found that BTNX Rapid Response™ nitazene test strips detected isotonitazene at 2000–3000 ng/mL depending on lot and cross-reacted with 24 of 33 tested nitazene analogues at ≤9000 ng/mL. All six authentic powder samples tested positive, but desnitazenes and some linker-modified analogues may be missed.

Key findings

  • The isotonitazene limit of detection was 3000 ng/mL for lot A and 2000 ng/mL for lot B, based on both visual and ImageJ scoring; the manufacturer lists a 2000 ng/mL cut-off.
  • Twenty-four of 33 nitazene analogues cross-reacted at concentrations ≤9000 ng/mL, while 9 were not detectable at 9000 ng/mL.
  • Structural analysis indicated that removal/substitution of the 5-nitro group (desnitazenes) or lengthening the linker between aromatic rings generally hampered detection; modifications at the para-benzyl position or amine side chain did not.
  • All six authentic powder samples containing metonitazene, protonitazene, isotonitazene, butonitazene, or N-pyrrolidino etonitazene tested positive, with no observed false negatives; LC-QTOF-MS estimated the nitazene analogue as the major compound with >90% purity.

Methods

  • BTNX Rapid Response™ NTS from two manufacturing lots were tested with isotonitazene standards in water at 500–3000 ng/mL, with six replicates per concentration across three days; readouts were scored by two blinded raters and by ImageJ, using 10-min results.
  • Cross-reactivity was evaluated for 32 additional nitazene analogues plus isotonitazene, initially at 3000 ng/mL, then at 1000 and/or 9000 ng/mL depending on the result; each compound was tested once per specified concentration.
  • Six sourced powder samples were tested by adding 1 mg powder to 1 mL tap water, then a 1/10 dilution, and comparing NTS results with LC-QTOF-MS characterization.

Limitations

  • The paper states that visual strip interpretation is subjective, that competitive NTS results can be misinterpreted, that test lines were consistently fainter than control lines, and that lot-to-lot variability exists; both lots were obtained within about four months, and cross-reactivity/authentic testing used only lot B.
  • The paper states that the authentic powders were likely highly pure and may not represent real-world samples, that incomplete dissolution occurred, that no NMR or salt-form characterization was performed, and that selectivity testing was not repeated except for brorphine at 1 mg/mL.
  • The paper states that trace nitazene amounts below the cut-off may be missed, desnitazenes may yield false negatives, and a negative result does not mean a sample is safe; evident from the text, the cross-reactivity panel used n = 1 per concentration and the authentic sample set was small (n = 6).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12954-024-01078-8

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Example of nitazene test strip images obtained from the limit of detection experiments, along with their visually assigned scores by two independent raters and their ImageJ scores. If both raters were confident that a test line was present or absent, the test was scored as negative (‘-’) (a-e) or positive (‘+’) (g), respectively. The test was indeterminate (‘?’) (f) if at least one of the raters had a lack of confidence in assessing the readout. The images depict one representative readout for each tested concentration of isotonitazene from NTS lot A, selected from a total of 6 replicate measurements conducted on three different days, with duplicates run each day (Fig. 2)
Fig. 1 Example of nitazene test strip images obtained from the limit of detection experiments, along with their visually assigned scores by two independent raters and their ImageJ scores. If both raters were confident that a test line was present or absent, the test was scored as negative (‘-’) (a-e) or positive (‘+’) (g), respectively. The test was indeterminate (‘?’) (f) if at least one of the raters had a lack of confidence in assessing the readout. The images depict one representative readout for each tested concentration of isotonitazene from NTS lot A, selected from a total of 6 replicate measurements conducted on three different days, with duplicates run each day (Fig. 2)CC BY-NC-ND · PubMed Central
Fig. 2 Overview of limit of detection results for BTNX Rapid Response™ nitazene test strips for isotonitazene from two different manufacturing lots, as obtained by visual assessment (left) and ImageJ analysis (right) (n = 6). Negative results (‘-’) are indicated by a red rectangle, positive results (‘+’) by a green rectangle, and indeterminate results ('?') by an orange rectangle
Fig. 2 Overview of limit of detection results for BTNX Rapid Response™ nitazene test strips for isotonitazene from two different manufacturing lots, as obtained by visual assessment (left) and ImageJ analysis (right) (n = 6). Negative results (‘-’) are indicated by a red rectangle, positive results (‘+’) by a green rectangle, and indeterminate results ('?') by an orange rectangleCC BY-NC-ND · PubMed Central
Fig. 3 Cross-reactivity of BTNX NTS for 33 screened nitazene analogues at 3000 ng/mL and at 1000 and/or 9000 ng/mL. A negative result (‘-’), positive result (‘+’), or indeterminate result (‘?’) is represented by a red, green, or orange rectangle, respectively. The asterisks denote that for N-pyrrolidino 4’-hydroxy nitazene (9) and for N-piperidinyl etonitazene (16) the results from two independent testings are shown, as the first experiment yielded a discrepant result: ImageJ indicated a negative result at 3000 ng/mL and a positive result at 1000 ng/mL. For both substances, the retesting did not yield this discrepancy
Fig. 3 Cross-reactivity of BTNX NTS for 33 screened nitazene analogues at 3000 ng/mL and at 1000 and/or 9000 ng/mL. A negative result (‘-’), positive result (‘+’), or indeterminate result (‘?’) is represented by a red, green, or orange rectangle, respectively. The asterisks denote that for N-pyrrolidino 4’-hydroxy nitazene (9) and for N-piperidinyl etonitazene (16) the results from two independent testings are shown, as the first experiment yielded a discrepant result: ImageJ indicated a negative result at 3000 ng/mL and a positive result at 1000 ng/mL. For both substances, the retesting did not yield this discrepancyCC BY-NC-ND · PubMed Central
Fig. 4 Structures of the 33 evaluated nitazene analogues that were detected (green background) or not (red background) by the BTNX NTS, with the employed experimental set-up. The highlighted groups correspond to modifications that occur at four distinct positions of the 2-benzylbenzimidazole core structure: (a) the para-benzyl position (blue), (b) the 5-position of the benzimidazole ring (purple), (c) the substituted ethyl amino side chain linked to the benzimidazole ring (orange), and (d) the linker between the two aromatic rings (pink). * Tested nitazene analogues that have been identified on the recreational drug market in Europe between 2019 and 2023 (14 in total) (EUDA)
Fig. 4 Structures of the 33 evaluated nitazene analogues that were detected (green background) or not (red background) by the BTNX NTS, with the employed experimental set-up. The highlighted groups correspond to modifications that occur at four distinct positions of the 2-benzylbenzimidazole core structure: (a) the para-benzyl position (blue), (b) the 5-position of the benzimidazole ring (purple), (c) the substituted ethyl amino side chain linked to the benzimidazole ring (orange), and (d) the linker between the two aromatic rings (pink). * Tested nitazene analogues that have been identified on the recreational drug market in Europe between 2019 and 2023 (14 in total) (EUDA)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

8 Valid · 3 Not valid · 14 Not checked · 65 Own results and interpretations

48 more claims

Create a free account to see all 90 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 25
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 34 references

Research works printed but not linked: 1

  1. Krotulski A, Shinefeld J, DeBord J, Teixeira da Silva D, Logan B. Evaluation of xylazine test strips (BTNX) for drug checking purposes. United States: Center for Forensic Science Research and Education; 2023.

Cited by

See all 34

Metadata

Authors
De Vrieze, L. M., Stove, C. P., & Vandeputte, M. M.
Affiliations
Ghent University (BE)
Corresponding author
  • Stove, Christophe P.
  • Vandeputte, Marthe M.
Venue
Harm Reduction Journal
Published
2024-08-28
Volume
21
Issue
1
Pages
159-159
ISSN
1477-7517 (ISSN-L)
OpenAlex
W4401968264
Cited by
34
References
34
Citations by year
2026: 15 · 2025: 19
FWCI
8.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Harm Reduction Journal (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Fonds Wetenschappelijk Onderzoek (11I5623N)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
  • Physical Sciences › Engineering › Biomedical Engineering › Biosensors and Analytical Detection
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
Keywords
nitazenes, isotonitazene, lateral flow immunoassay, drug checking, cross-reactivity, detection limit, heroin adulteration, opioid toxicity
MeSH terms
Analgesics, Opioid, Humans, Immunoassay, Nitro Compounds, Reagent Strips, Substance Abuse Detection, Limit of Detection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nitazene test strips: a laboratory evaluation. https://app.cochat.ai/papers/10.1186/s12954-024-01078-8
The paper
De Vrieze, L. M., Stove, C. P., & Vandeputte, M. M. (2024). Nitazene test strips: a laboratory evaluation. Harm Reduction Journal. https://doi.org/10.1186/s12954-024-01078-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.